Experienced protein chemist and biophysicist with >10 years experience purifying, conjugating, and characterizing challenging tissue-derived/endogenous and recombinantly expressed protein targets to generate fit-for-purpose proteins which support programs and advance projects.Additional expertise in:Project management Molecular biology AKTA/Unicorn method development/optimization Bacterial and mammalian cell culture Biochemical & plate-based assay development and transfer New target evaluation Supervision and mentorship of junior scientistsI currently work in the pharmaceutical industry as a protein biochemist purifying and characterizing challenging proteins. My work at Prothena involved all aspects of drug discovery from target evaluation and discovery biology to mAb developability/stability studies and IND report writing. Key accomplishments and contributions: -Principal protein scientist on 3 campaigns, significant contributions to entire pipeline-Purified >100 proteins and mutants to support components of all aspects of drug discovery: target evaluation, discovery biology, characterization, development, and manufacturing-HCP assay (development, data collection, analysis, IND report)-in-vivo efficacy biochemical evaluation-in-vivo disease model biochemistry-in-vitro disease model biochemistry-Lot release assay (development, data collection, analysis, report writing, assay transferred to GxP)-mAb developability and stability study design, data collection, and analysis-Immunoassay development (IP, immunodepletion, etc)-In-house bioconjugation and bacterial expression expertMy post-doctoral work involved studying the structure and function of epigenetic readers and writers.Key accomplishments: 3 published manuscripts (see below), crystal tray setup and screening, protein modeling, restriction/gateway cloningMy graduate research focused on the aggregation of microtubule associated protein (MAP) Tau. Tau fibrils are a hallmark of 20+ neurodegenerative diseases. My doctoral work provided insights into conformational ensembles and conformational evolution through the use of a variety of techniques like TEM, FRET, fluorescence anisotropy, and cell-based assays to illustrate the need to further investigate how fibril strains and heterogeneity can lead to different phenotypic presentations and clinical consequences.Key accomplishments: 4 published papers, supervised >5 undergraduate thesis projects, purified >21 unique proteins (>50 including mutants)